Brentuximab vedotin begins new trial for Hodgkin's lymphoma
This article was originally published in Scrip
Executive Summary
Seattle Genetics and Takeda have begun a Phase III trial with the antibody-drug conjugate brentuximab vedotin in patients at high risk of residual Hodgkin's lymphoma (HL) following autologous stem cell transplant (ASCT).